

Development of Targeted Therapeutics for Left Atrial Myopathy in HFpEF

presented by

Sanjiv Shah, MD

12/19/2023 12:00:00 PM

Learning Objectives: *As a result of participating in this Live Activity, participants should be able to:*

- 1 discuss current guidelines in order to provide optimal care to admitted medical and surgical cardiac patients*
- 2 apply current guidelines in order to provide optimal care to admitted medical and surgical cardiac patients*
- 3 review current cases in order to apply the latest evidence based recommendations for treatment*
- 4 identify opportunities for additional education, multispecialty collaboration, and quality improvement in the Heart and Vascular Institute*

Accreditation Statement: In support of improving patient care, Hartford HealthCare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement: Hartford Healthcare designates this Live Activity for 1.00 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with their participation. This activity is approved for 1.00 ANCC contact hour(s).

Financial Disclosures:

- Sanjiv Shah, MD : Grant or research support-National Institutes of Health|Grant or research support-Actelion Pharmaceuticals Actelion Pharmaceuticals|Grant or research support-AstraZeneca (Any division)|Grant or research support-Corvia|Grant or research support-Novartis Corporation Pharmaceuticals|Grant or research support-Pfizer (Any division)|Consulting Fee-Abbott (Any division)|Consulting Fee-AstraZeneca (Any division)|Consulting Fee-Amgen|Consulting Fee-Aria CV|Consulting Fee-Axon Therapies|Consulting Fee-Bayer (Any division)|Consulting Fee-Boehringer Ingelheim Pharmaceuticals, Inc.|Consulting Fee-Boston Scientific Corporation|Consulting Fee-Bristol-Myers Squibb|Consulting Fee-Cardiora|Consulting Fee-Cordiora|Consulting Fee-

CVRx|Consulting Fee-Cytokinetics|Consulting Fee-Edwards Lifesciences Corporation|Consulting Fee-Eisai, Inc.|Consulting Fee-Eidos|Consulting Fee-Imara|Consulting Fee-Impulse Dynamics|Consulting Fee-GSK|Consulting Fee-Intellia|Consulting Fee-Ionis Pharmaceuticals|Consulting Fee-Ironwood|Consulting Fee-Lilly|Consulting Fee-Merck (Any division)|Consulting Fee-MyoKardia, Inc.|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Novo Nordisk (Any division)|Consulting Fee-Pfizer (Any division)|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Prothena|Consulting Fee-Rivus|Consulting Fee-Sanofi S.A.|Consulting Fee-Sardocor|Consulting Fee-Shifamed|Consulting Fee-Tenax|Consulting Fee-Tenaya|Consulting Fee-United Therapeutics - 10/26/2023



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION